

Cost Benefit Analysis

Data Source: <https://diabetesjournals.org/care/article/41/5/929/36592/The-Cost-of-Diabetes-Care-An-Elephant-in-the-Room>

For conducting the cost benefit analysis based on our predicted model and confusion matrix, we need to understand the cost and benefits associated to our model in the following details-

Incurs Cost/year:

Unnecessary test, treatments and follow-ups **costs** for each patient: We assume this cost would be approx. 20% of their each year costs.

- **Benefits**

Healthcare Savings (Indirect benefits): Reduced costs due to fewer hospitalizations, emergency room visits, and complications related to diabetes.

Productivity Gains (Indirect benefits): Improved workforce productivity due to better diabetes management.

Long-term Savings and contribution for USA economy (Direct benefits): Prevention of diabetes in high-risk individuals leading to long-term healthcare cost savings. As a result unnecessary test, treatments and follow ups money will directly contribute in USA economy from spending 20% of total required each patients cost.

- **Data Points**

From the confusion matrix, we got the following observations:

True Positives (TP): 26868 (correctly predicted as having diabetes)

False Positives (FP): 15595 (incorrectly predicted as having diabetes)

True Negatives (TN): 202739 (correctly predicted as not having diabetes)

False Negatives (FN): 8448 (incorrectly predicted as not having diabetes)

- **Assumptions**

Cost per Diabetes Patient: \$16752 per year as mentioned in website source

FP Cost: Costs related to unnecessary test, treatment, stress, and follow-up tests.

TP Savings: Savings from early intervention and preventing complications.

Indirect Costs: Productivity loss, quality of life impacts, etc.

- **Calculations**

- **Total Costs without the Model**

Current Annual Cost: $\$16752 * 35346 = \text{approx. } \592.02 million for diagnosed patients.

- **Cost with the Model**

FP Costs: Also let's do an additional cost of \$1,000 per FP due to unnecessary treatments and follow-ups.

TP Savings: Assume savings of 20% per TP due to early intervention ($\$16752 * 20\% = \3350.40).

- **Benefit Analysis**

Total Cost Savings: No. of TPs * Savings per TP = $26898 \times \$3350.40 = \90.127 million

Total Additional Costs: No. of FPs * Additional cost per FP = $15595 * \$1000 = \15.555 million

- **Net Benefit**

Net Benefit = Total Cost Savings - Total Additional Costs = $\$90.127 \text{ million} - \15.555 million
= approx. $\$74.532 \text{ million}$

➤ **Total Costs with the new Model :** $\$592.02 - \$90.127 + \$15.555 = \517.488 million

Summary:

- Total Annual Cost without the Model: approx. $\$592.02 \text{ million}$
- Net Benefit of Implementing the Model: approx. $\$74.532 \text{ million}$

And then Total Annual Cost with the Model: approx. $\$517.488 \text{ million}$

So if we implement the predictive model for type 2 diabetes, it will reduce the annual cost for diabetes from $\$592.02 \text{ million}$ to $\$517.488 \text{ million}$, resulting in annual savings of $\$74.532 \text{ million}$.